EP1660656B1 - An antisense oligonucleotide to inhibit melanoma inhibitory activity, mia - Google Patents

An antisense oligonucleotide to inhibit melanoma inhibitory activity, mia Download PDF

Info

Publication number
EP1660656B1
EP1660656B1 EP04763992A EP04763992A EP1660656B1 EP 1660656 B1 EP1660656 B1 EP 1660656B1 EP 04763992 A EP04763992 A EP 04763992A EP 04763992 A EP04763992 A EP 04763992A EP 1660656 B1 EP1660656 B1 EP 1660656B1
Authority
EP
European Patent Office
Prior art keywords
antisense
oligonucleotide
mia
bases
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04763992A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1660656A2 (en
Inventor
Karl-Hermann Schlingensiepen
Reimar Schlingensiepen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Isarna Therapeutics GmbH
Original Assignee
Antisense Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antisense Pharma GmbH filed Critical Antisense Pharma GmbH
Priority to EP04763992A priority Critical patent/EP1660656B1/en
Publication of EP1660656A2 publication Critical patent/EP1660656A2/en
Application granted granted Critical
Publication of EP1660656B1 publication Critical patent/EP1660656B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/311—Phosphotriesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Definitions

  • the present invention relates to an antisense oligonucleotide or modifications thereof for the inhibition of the expression and/or functional activity of Melanoma Inhibitory Activity "MIA", a pharmaceutical composition comprising the oligonucleotide or modifications thereof and its use for the prevention or the treatment of neoplasms, infections and /or immunosuppressive disorders.
  • MIA Melanoma Inhibitory Activity
  • MIA melanoma Inhibitory Activity
  • MIA Peripheral Blood Mononuclear Cells
  • MIA a 131-amino acid precursor, processed into a mature 107-amino acid protein. This publication confirmed that MIA acts as a potent tumor cell growth inhibitor for malignant melanoma cell and further extended this observation to other neuroectodermal tumors. They concluded that ,”... MIA ... might be attractive as a future antitumor therapeutical substance" ( Cancer Res. 54; 5695-5701, 1994 ).
  • Bosserhoff et al. observed that MIA specifically inhibits attachment of melanoma cells to fibronectin and laminin thereby masking the binding sites of integrins to these extracellular matrix components and promoting invasion and metastasis in vivo ( Bosserhoff et al., Hautech 49, 762-769, 1998 ; Stoll et al., EMBO J 20, 340-349, 2001 _).
  • the growth-inhibitory activity in vitro may therefore reflect the ability of MIA to interfere with the attachment of cells to culture dishes observed by Blesch et al. (Cancer Res. 54; 5695-5701, 1994 ).
  • MIA myeloma
  • GIA levels were measured in cerebrospinal fluid specimens from patients with spinal diseases ( Natsume et al., Spine 26(2): 157-60, 2001 ).
  • MIA concentration of MIA in cervical myelopathy, lumbar canal stenosis, and lumbar disc herniation was significantly higher than in the control group. Interestingly, MIA is not expressed in the central nervous system under physiological conditions.
  • MIA in situ-hybridization experiments, as well as immuno histochemistry localize MIA in the developmental embryo within the growth zone of the skeletal system, and it is being expressed, secreted, and deposited around the chondrocytes. Additionally, it is pathologically expressed in chondrosarcoma ( Bosserhoff et al., Dev Dyn 208(4): 516-525, 1997 ).
  • MIA rheumatoid arthritis and cartilage damage.
  • Muller-Ladner et al. found increased MIA serum concentrations in patients with rheumatic diseases with joint destruction, osteoarthritis, HLA-27-asscociated oligoarthritis, psoriatic arthritis and rheumatic arthritis, where the most significant increase in MIA was found ( Muller-Ladner et al., Rheumatology 38; 148-154, 1999 ).
  • MIA MIA was found to be expressed and secreted into the serum by all of the malignant melanomas examined, but not in other skin tumor, including basal cell cancer and squamous cell cancer, nor in normal melanocytes and keratinocytes ( Bosserhoff et al., J Pathol 187(4):446-454, 1999 ). Additionally, MIA expression was further found in all advanced stage breast cancer and metastases analyzed suggesting a much broader expression of MIA in malignant epithelial neoplasms than previously determined by serum studies ( Bosserhoff et al., J Pathol 187(4): 446-454, 1999 ).
  • Molecules for the inhibition of the expression and/or functional activity of MIA are published in WO 01/68122 .
  • the inhibition is achieved by using at least one nucleic acid molecule, peptide, protein or low molecular weight substance, wherein the nucleic acid molecule is an oligo- or polynucleotide molecule, in particular an antisense molecule and/or ribozyme.
  • the above mentioned patent-application relates to molecules including oligonucleotides able to inhibit the expression and/or function of MIA and thereby reversing the immunosuppression ( WO 01/68122 ).
  • the present invention relates to antisense-oligonucleotides with the following sequence 5'- TTG CAT AAA CCC AAG GAG - 3', modifications thereof, parts of the antisense oligonucleotide with at least 8 nucleotides and/or modifications thereof. They show a surprisingly much more effective inhibition of the expression and/or function of "Melanoma Inhibitory Activity" MIA, thereby eliciting a more effective inhibition of tumor invasion and/or inhibition of metastasis and for a more effective stimulation of immune cells and/or the immune system than antisense-oligonucleotides of the prior art.
  • the present invention also pertains to a pharmaceutical composition comprising at least one of the antisense oligonucleotides or modifications thereof and to its use for the prevention or the treatment of neoplasms, infections and /or immunosuppressive disorders.
  • the antisense oligonucleotide having the sequence 5'- TTG CAT AAA CCC AAG GAG or modifications thereof has a DNA- or RNA-type structure able to hybridize to an area of the gene region coding MIA and thereby reducing and/or inhibiting the expression of MIA. It is also understood by persons skilled in the art that fragments having subsequences of the above given antisense oligonucleotide with at least 8 nucleotides or modifications thereof work according to the invention so long as production of MIA is reduced or inhibited.
  • the antisense oligonucleotide with the sequence 5'- TTG CAT AAA CCC AAG GAG and antisense oligonucleotides representing parts of the this sequence with at least 8 nucleotides are referred to as the antisense oligonucleotides.
  • the antisense oligonucleotides are modified at one or more of the sugar moieties, the bases and/or the internucleotide linkages as well as the phosphate moieties.
  • the modifications of the oligonucleotides comprise modifications such as phosphorothioate (S-ODN) internucleotide linkages, methylphosphonate internucleotide linkages, phosphoramidate linkages, peptide linkages, 2'-O-alkyl modifications of the sugar, in particular methyl, ethyl, propyl, butyl and the like, 2'-methoxyethoxy modifications of the sugar and/or modifications of the bases.
  • S-ODN phosphorothioate
  • methylphosphonate internucleotide linkages phosphoramidate linkages
  • peptide linkages 2'-O-alkyl modifications of the sugar, in particular methyl, ethyl, propyl, butyl and the like, 2'-
  • the ring structure of the ribose group of the nucleotides in the modified oligonucleotide or polynucleotide has the oxygen in the ring structure substituted with N-H, N-R, S and/or methylene.
  • the backbone modifications include 2'-O-methylribonucleosides (2 '-0-Me). These types of substitutions are described extensively in the literature and in particular with respect to their immunostimulating properties in Zhao et al., Bioorganic and Medicinal Chemistry Letters, 1999, 9:24:3453 . Zhao et al. describes methods of preparing 2-0--Me modifications to nucleic acids, herein incorporated by reference.
  • the 3' and/or 5' ends of the oligoribonucleotide sequence are preferably attached to exonuclease blocking groups.
  • a partial list of blocking groups includes inverted bases, 2'- or 3'-O-aryl nucleotides (preferably the aryl is methyl, ethyl or propyl), dideoxynucleotides, methylphosphates, alkyl groups, aryl groups, cordycepin, cytosine arabanoside, phosphoramidates, a peptide linkage, dinitrophenyl group, fluorescein, cholesterol, biotin, biotin analogs, avidin, avidin analogs, strepavidin, acridine, rhodamine, psoralen, glyceryl, methyl phosphonates, butanol, butyl, hexanol, and 3'-O-alkyls.
  • At least one blocking group is a biotin, biotin analog, avidin, or avidin analog. These molecules have the ability to both 1) block the degradation of the protected oligonucleotide or polynucleotide and 2) provide means for high affinity attachment of the modified nucleic acids to the solid support.
  • Avidin and biotin derivatives which can be used to prepare the reagents of this invention include streptavidin, succinylated avidin, monomeric avidin, biocytin (biotin-.epsilon.-N-lysine), biocytin hydrazide, amine or sulfhydryl derivatives of 2-iminobiotin and biotinyl-.epsilon.-aminocaproic acid hydrazide.
  • biotin derivatives such as biotin-N-hydroxysuccinimide ester, biotinyl-.epsilon.-aminocaproic acid-N-hydroxysuccinimide ester, sulfosuccinimidyl 6-(biotin amido)hexanoate, N-hydroxysuccinimideiminobiotin, biotinbromoacetylhydrazide, p-diazobenzoyl biocytin and 3-(N-maleimidopropionyl)biocytin, can also be used as end-blocking groups on the polynucleotides of the present invention.
  • At least one end-block on the oligonucleotide is a biotin, biotin analog, avidin, or avidin analog. These molecules have the ability to both 1) block the degradation of the protected oligonucleotide or polynucleotide and 2) provide means for high affinity attachment of the modified nucleic acids to the solid support.
  • Avidin and biotin derivatives which can be used to prepare the reagents of this invention include streptavidin, succinylated avidin, monomeric avidin, biocytin (biotin-.epsiton.-N-lysine), biocytin hydrazide, amine or sulfhydryl derivatives of 2-iminobiotin and biotinyl-.epsilon.-aminocaproic acid hydrazide.
  • biotin derivatives such as biotin-N-hydroxysuccinimide ester, biotinyl-.epsilon.-aminocaproic acid-N-hydroxysuccinimide ester, sulfosuccinimidyl 6-(biotin amido)hexanoate, N-hydroxysuccinimideiminobiotin, biotinbromoacetylhydrazide, p-diazobenzoyl biocytin and 3-(N-maleimidopropionyl)biocytin, can also be used as end-blocking groups on the polynucleotides of the present invention.
  • the antisense-oligonucleotides or an effective modification thereof is a phosphorothioate-oligodeoxynucleotide.
  • the respective nucleotide is coupled to the first nucleoside, which is covalently attached to the solid phase comprising the steps of
  • Aryl-and alkyl-phosphonates can be made, e.g., as described in U.S. Pat. No. 4,469,863 ; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023,243 and European Patent No. 092,574 ) can be prepared by automated solid phase synthesis using commercially available reagents.
  • Additional methods of rendering oligonucleotide or polynucleotide polymers nuclease resistant include, but are not limited to, covalently modifying the purine or pyrimidine bases.
  • bases may be methylated, hydroxy-methylated, or otherwise substituted (e.g., glycosylated) such that the oligonucleotides or polynucleotides are rendered substantially acid and nuclease resistant.
  • heterocyclic bases are disclosed in U.S. Pat. No. 3,687,808, issued to Merigan, et al.
  • purines or “pyrimidines” or “bases” are used herein to refer to both naturally-occurring or synthetic purines, pyrimidines or bases.
  • oligonucleotides The chemical structure of oligonucleotides and their modifications are given in Figure 2.
  • the oligonucleotide chain is to be understood as a detail out of a longer nucleotide chain.
  • B means an organic base such as adenine (A), guanine (G), cytosine (C) or thymine (T) (shown in Figure 2b) in oligodeoxy-ribonucleotides and the bases adenine (A), guanine (G), cytosine (C), uracile (U) (shown in Figure 2c) in oligo-ribonucleotides.
  • the bases are coupled via the nitrogen N9 in the case of the bases A and G or the nitrogen N1 in the case of the bases C, T and U to the desoxyribose or ribose, respectively.
  • the sequence of the bases is the reverse complement of the genetic target sequence MIA.
  • oligodeoxy-ribonucleotides and oligo-ribonucleotides in Figure 2a are as follows, whereby both, oligodeoxy-ribonucleotides and oligo-ribonucleotides are referred to as oligonucleotides:
  • Modifications of the antisense-oligonucleotides are advantageous since they are not as fast destroyed by endogeneous factors when applied, as this is valid for naturally occurring nucleotide sequences.
  • the modification is a phosphorothioate modification.
  • Oligodeoxy-nucleotides are synthesized stepwise by 5' addition of protected nucleotides using phosphite triester chemistry.
  • the nucleotide A is introduced as 5'-dimethoxytrityl-deoxyadenosine (N 4 -benzoyl)-N,N'-diisopropyl-2-cyanoethyl phosphoramidite;
  • the nucleotide C is introduced by a 5'-dimethoxytrityl-deoxycytidine(N 4 -benzoyl)-N,N'-diisopropyl-2-cyanoethyl phosphoramidite;
  • the nucleotide G is introduced as 5'-dimethoxytrityl-deoxyguanosine(N 8 -isobutyryl)-N,N'-diisopropyl-2-cyanoethyl phosphoramidite and the nucleotide T is
  • Synthesis can be performed for example on controlled pore glass particles of approximately 150 mm diameter (pore diameter 500 ⁇ ) to which the 3' nucleoside is covalently attached via a long-chain alkylamin linker (average loading 30 ⁇ mol/g solid synthesis support).
  • the solid synthesis support is loaded into a cylindrical synthesis column, capped on both ends with filters permitting adequate flow of reagents but hold back the solid synthesis support.
  • Reagents are delivered and removed from the synthesis coiumn using positive pressure of inert gas.
  • the nucleotides are added to the growing oligonucleotide chain in 3' -> 5' direction. Each nucleotide is coupled using one round of the following synthesis cycle:
  • the unreacted 5'-hydroxyl groups are capped with simultaneous addition of 1-methylimidazole and acetic anhydryide / lutidine /tetrahydrofuran. Thereafter, the synthesis column is washed with acetonitrile and the next cycle is started.
  • the deoxynucleotides are cleaved from the solid support by incubation in ammonium solution. Exoxyclic base protecting groups are removed by further incubation in ammonia. Then the ammonium is evaporated under vacuum. Full-length synthesis products still bearing the 5'DMT protecting group are separated from shorter failure contaminants using reverse phase high performance liquid chromatography (HPLC) on reversed phase C 18 stationary phase. Eluents from the product peak are collected, dried under vacuum and the 5'-DMT protecting group cleaved by incubation in acetic acid, which is evaporated thereafter under vacuum. The synthesis products are solved in deionized water and extracted three times with diethylether. Then the products are dried in vacuum.
  • HPLC reverse phase high performance liquid chromatography
  • HPLC-AX HPLC - anion exchange
  • the antisense oligonucleotides or modifications thereof can be used for the stimulation of the immune system by inhibiting expression and/or functional activity of "Melanoma Inhibitory Activity" MIA.
  • the antisense oligonucleotides or modifications thereof are used in a combination with at least one of the molecules, viruses, peptides and/or cell extracts listed under a) to m:
  • the molecules including at least one antisense oligonucleotide, viruses, peptides and/or cell extracts listed under a) to m) can be applied by, to the following methods, whereby application is not limited to these methods:
  • the antisense oligonucleotides or modifications thereof can be combined with an immunostimulatory agent, selected from the group of cytokines and/or inhibitors of the expression and/or function of interleukin-10 and/or transforming growth factor beta (TGF- ⁇ ) and/or Prostaglandin B2 and/or receptors for Prostaglandin E2 and/or inhibitors of VEGF.
  • an immunostimulatory agent selected from the group of cytokines and/or inhibitors of the expression and/or function of interleukin-10 and/or transforming growth factor beta (TGF- ⁇ ) and/or Prostaglandin B2 and/or receptors for Prostaglandin E2 and/or inhibitors of VEGF.
  • the antisense oligonucleotides or modifications thereof can be combined with at least one of the following molecules, methods, peptides and/or cell extracts:
  • These molecules including at least one antisense oligonucleotide, peptides and/or cell extracts can be applied parenteral by intravenous, intraarterial, intraperitoneal, subcutaneous or intramuscular injection or infusion and/or locally by oral, epidermal, intradermal- and transdermal administration.
  • Preferred subjects for application are mammals, most preferred subjects are humans.
  • the coding sequences of the antisense oligonucleotides are integrated into a DNA delivery system, comprising viral and/or non-viral vectors together with lipids selected from the group of anionic lipids, cationic lipids, non-cationic lipids and mixtures thereof.
  • the antisense oligonucleotides thus may contain flanking sequences and/or vector sequences and/or sequences enhancing the expression and/or transfection of the nucleic acid molecules.
  • the coding sequences of the antisense oligonucleotides are part of one or more vectors and/or viral sequences and/or viral vectors.
  • the antisense oligonucleotides or modifications thereof are coupled to or mixed with folic acid, hormones, steroid hormones such as oestrogene, progesterone, corticosteroids, mineral corticoids, peptides, proteoglycans, glycolipids, phospholipids and derivatives thereof.
  • hormones such as oestrogene, progesterone, corticosteroids, mineral corticoids, peptides, proteoglycans, glycolipids, phospholipids and derivatives thereof.
  • the antisense oligonucleotides or modifications thereof can be used for the preparation of a medicament.
  • the antisense oligonucleotides is combined with one or more of the afore mentioned immunostimulatory agents for the preparation of a medicament, wherein the medicament can be applied locally or systemically to a tumor or other pathologically affected site or organ.
  • the medicament is used for the prevention or the treatment of neoplasms and disorders selected from the group of melanoma, gastrointestinal carcinoma, breast cancer, pancreatic cancer, ovarial carcinoma, chondrosarcoma, spinal diseases, cervical myelopathy, lumbar canal stenosis, lumbar disc herniation, rheumatoid arthritis, osteoarthritis, HLA-27-asscociated oligoarthritis, psoriatic arthritis and rheumatic arthritis, cartilage damage and/or joint destruction.
  • the effective amount of oligonucleotide applied varies depending upon whether the pharmaceutical composition is used in single or multiple dosages and whether only one or several antisense oligonucleotides are within one pharmaceutical composition.
  • the effective dosage is dependent also on the method and means of administration.
  • Routes of administration include, but are not limited to, electrocorporation, epidermal, impression into skin, intra-arterial, intra-articular, intrabuccal, intra-cranial, intra-dermal, intra-lesional, intra-muscular, intranasal, intraocular, intra-peritoneal, intra-prostatic, intra-pulmonary, intra-spinal, intrathecal, intratracheal, intra-tumoral, intra-venous, intra-vesical, placement within cavities of the body, nasal inhalation, oral, pulmonary inhalation (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer), subcutaneous, subdermal, topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery) and transdermal.
  • electrocorporation epidermal, impression into skin
  • subject doses of the oligonucleotides described herein typically range from about 0.05 ⁇ g/kg to about 500 mg/kg, preferred about 1 ⁇ g/kg to about 100 mg/kg, and more preferred from about 100 ⁇ g/kg to about 50 mg/kg per administration, which could be given hourly, daily, weekly, or monthly and any other amount of time therebetween depending on the mode of application.
  • doses may be used in a range even 2 to 100 fold higher or lower than the typical doses described above.
  • the upper limit of the dosages given above may be up to1 mg/kg or even up to about 5 mg/kg.
  • the application of the oligonucleotide in solution is given in continuous infusion, in yet another embodiment several bolus injections or short term infusions of the solution are applied.
  • Doses of the oligonucleotides administered by infusion typically range from about 0.05 ⁇ g/kg/day to about 100 mg/kg/day, more preferred from about 1 ⁇ g/kg/day to about 50 mg/kg/day, and more preferred from about 100 ⁇ g/kg/day to about 30 mg/kg/day.
  • the infusion or bolus injection is repeated about 1 to 100 times or even more, more preferred about 3 to about 30 times and even more preferred 5 to about 10 times.
  • Short term infusion in the context of this application means infusions from about 0.1 h to about 4 h, more preferred from about 0.5 h to about 3 h and most preferably from about 1 h to about 2 h.
  • Continuous infusion in the context of this application means infusions from about 5 h up to about 24 h, several days, weeks or even months.
  • Continuous infusions in special embodiments are repeated about 1 to 100 times and even more, in other embodiments they are repeated about 3 to about 30 times and in yet other embodiments about 5 to about 10 times.
  • isotonic solutions such as standard infusion solutions, e.g. 0.9% sodium chloride solution, Ringer-lactate solution, dextranes etc. are applied.
  • oligonucleotides of this invention are applied purely or in a pharmaceutical acceptable carrier.
  • Pharmaceutical acceptable carrier in the context of this invention means any pharmaceutical composition or formulation suitable for the administration of the oligonucleotide.
  • compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets.
  • compositions and formulations for parenteral application the oligonucleotides are solved in sterile aqueous solutions which may also contain buffers, diluents and other suitable additives e.g. carrier compounds, other pharmaceutically acceptable carriers or excipients.
  • suitable additives e.g. carrier compounds, other pharmaceutically acceptable carriers or excipients.
  • compositions and formulations for topical administration include transdermal patches, ointments, lotions, drops, creams, gels, sprays, liquids and powders.
  • compositions and formulations for rectal administration comprise ointments, creams, gels, suppositories and liquids.
  • compositions and formulations for nasal administration comprise ointments, creams, gels, drops, sprays liquids and powders.
  • compositions and formulations comprise sprays and powders.
  • compositions and formulations for the above mentioned pharmaceutical compositions and formulations, pharmaceutical carriers, penetration enhancers, aqueous, powder or oily bases, thickeners, flavoring agents, diluents, emulsifiers, dispersing aids, binders and other excipients may be may be added.
  • Compositions and formulations for oral administration in one embodiment are enteric coated.
  • the antisense compounds of the invention are useful also for research and diagnostics, because these compounds hybridize to the nucleic acid encoding MIA, enabling sandwich and other assays to easily be constructed to exploit this fact.
  • Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding MIA can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of MIA in a sample may also be prepared.
  • DMEM/10% FCS 1ml medium
  • DMEM/10% FCS 1ml medium
  • the cells were transfected with 200 nM of antisense oligonucleotide using Lipofectin (Gibco BRL, Eggenstein, Germany) according to the manufacturers protocol.
  • Each antisense oligonucleotide was transfected in triplicates.
  • the cells were cultured in DMEM/10% FCS containing 5 ⁇ M of the respective antisense oligonucleotide for further three days. The supernatants were taken and stored at -20°C until quantification of MIA-Protein.
  • MIA concentrations in the supernatant were measured employing ELISA according to the manufacturers protocol (Roche, Boehringer Mannheim, Germany).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP04763992A 2003-08-12 2004-08-11 An antisense oligonucleotide to inhibit melanoma inhibitory activity, mia Expired - Lifetime EP1660656B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04763992A EP1660656B1 (en) 2003-08-12 2004-08-11 An antisense oligonucleotide to inhibit melanoma inhibitory activity, mia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03018285 2003-08-12
PCT/EP2004/008986 WO2005014812A2 (en) 2003-08-12 2004-08-11 An antisense oligonucleotide to inhibit melanoma inhibitory activity, mia
EP04763992A EP1660656B1 (en) 2003-08-12 2004-08-11 An antisense oligonucleotide to inhibit melanoma inhibitory activity, mia

Publications (2)

Publication Number Publication Date
EP1660656A2 EP1660656A2 (en) 2006-05-31
EP1660656B1 true EP1660656B1 (en) 2007-08-08

Family

ID=34130073

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04763992A Expired - Lifetime EP1660656B1 (en) 2003-08-12 2004-08-11 An antisense oligonucleotide to inhibit melanoma inhibitory activity, mia

Country Status (7)

Country Link
US (1) US7910563B2 (ja)
EP (1) EP1660656B1 (ja)
JP (1) JP4649408B2 (ja)
AT (1) ATE369422T1 (ja)
DE (1) DE602004008085T2 (ja)
ES (1) ES2289544T3 (ja)
WO (1) WO2005014812A2 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910563B2 (en) 2003-08-12 2011-03-22 Antisense Pharma Gmbh Antisense oligonucleotide to inhibit melanoma inhibitory activity, MIA
CN100562342C (zh) * 2006-01-17 2009-11-25 奥林格斯技术有限公司 防治流感病毒感染的寡核苷酸药物
AU2011263642B2 (en) 2010-06-11 2014-09-04 Isarna Therapeutics Gmbh Method for selective oligonucleotide modification
ITRM20110134A1 (it) * 2011-03-22 2012-09-23 Matteo Bordignon Inibitori di mia (attività inibitoria melanoma) per identificare, prevenire e curare la vitiligine
EP3103450A1 (en) 2015-06-12 2016-12-14 Friedrich-Alexander-Universität Erlangen-Nürnberg None-hydrophobic compounds for use in treating metastasis and/or cartilage defect
CN105250900A (zh) * 2015-10-21 2016-01-20 宋军君 一种治疗腰椎间盘突出中药
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
KR101843984B1 (ko) 2016-02-09 2018-03-30 오토텔릭 엘엘씨 췌장암을 치료하기 위한 조성물과 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0945507A1 (de) * 1998-03-27 1999-09-29 Boehringer Mannheim Gmbh Tumorspezifische Expressionskontrollregion und deren Verwendung
WO1999065928A2 (en) 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
EP1133994A1 (en) * 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA"
AU2001250572A1 (en) * 2000-04-07 2001-10-23 Epigenomics Ag Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
US7910563B2 (en) 2003-08-12 2011-03-22 Antisense Pharma Gmbh Antisense oligonucleotide to inhibit melanoma inhibitory activity, MIA

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
JP4649408B2 (ja) 2011-03-09
WO2005014812A2 (en) 2005-02-17
ATE369422T1 (de) 2007-08-15
US20070299022A1 (en) 2007-12-27
WO2005014812A3 (en) 2005-06-09
EP1660656A2 (en) 2006-05-31
DE602004008085D1 (de) 2007-09-20
ES2289544T3 (es) 2008-02-01
JP2007501621A (ja) 2007-02-01
US7910563B2 (en) 2011-03-22
DE602004008085T2 (de) 2008-04-24

Similar Documents

Publication Publication Date Title
JP6865871B2 (ja) 酸性α−グルコシダーゼにおけるアンチセンス誘導エクソン２包含
US6187585B1 (en) Oligonucleotide inhibition of epidermal growth factor receptor expression
JP6382150B2 (ja) ｍＲＮＡ前駆体のスプライシングを修飾するＥＮＡ核酸医薬
Astriab-Fisher et al. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions
JP5650367B2 (ja) 医薬組成物
EP1282699B1 (en) Splice-region antisense composition and method
CA2209989A1 (en) Compositions and methods for treating tumor cells
US20220010309A1 (en) Synthesis of modified oligonucleotides with increased stability
RU2249458C2 (ru) Олигонуклеотиды для ингибирования экспрессии eg5 человека
JP7033547B2 (ja) 酸性アルファ－グルコシダーゼ遺伝子に関連する疾患を処置するためのアンチセンスオリゴマーおよびそれを用いる方法
WO1998033904A2 (en) An antisense oligonucleotide preparation method
US6001991A (en) Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
JP2022528840A (ja) 安定性が増加した修飾オリゴヌクレオチド
EP2399611B1 (en) Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formaton of metasatases in cancer treatment
US5910583A (en) Antisense oligonucleotides against ERBB-2
JP2018518148A (ja) ミオスタチンにおけるアンチセンスに誘導されるエクソンの排除
EP1660656B1 (en) An antisense oligonucleotide to inhibit melanoma inhibitory activity, mia
JP2000514093A (ja) Ｃｍｖ感染症の治療のための組成物および方法
JP2002501505A (ja) ヒトＨａ−ｒａｓ遺伝子断片に相補的な修飾アンチセンスヌクレオチド
CN117858949A (zh) 用于抑制粘蛋白5AC(MUC5AC)的表达的RNAi试剂、其组合物及其使用方法
WO2023176863A1 (ja) ＲＮＡｉ活性を有する化学修飾オリゴヌクレオチド
MXPA01000908A (en) Short oligonucleotides for the inhibition of vegf expression

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060124

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20060705

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004008085

Country of ref document: DE

Date of ref document: 20070920

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SCHMAUDER & PARTNER AG PATENTANWALTSBUERO

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070808

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071108

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070808

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2289544

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070808

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071109

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070808

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070808

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080108

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070808

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071108

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070808

26N No opposition filed

Effective date: 20080509

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070813

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070808

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070808

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070808

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: SCHMAUDER & PARTNER AG PATENT- UND MARKENANWAELTE VSP;ZWAENGIWEG 7;8038 ZUERICH (CH)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070808

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080209

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20100922

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20110824

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20110822

Year of fee payment: 8

Ref country code: FR

Payment date: 20110829

Year of fee payment: 8

Ref country code: GB

Payment date: 20110824

Year of fee payment: 8

Ref country code: ES

Payment date: 20110825

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20110824

Year of fee payment: 8

Ref country code: BE

Payment date: 20110822

Year of fee payment: 8

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004008085

Country of ref document: DE

Representative=s name: BETTINA CELIA HERMANN, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004008085

Country of ref document: DE

Representative=s name: VEREENIGDE OCTROOIBUREAUX N.V., DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004008085

Country of ref document: DE

Representative=s name: VEREENIGDE OCTROOIBUREAUX V.O., DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004008085

Country of ref document: DE

Representative=s name: VEREENIGDE OCTROOIBUREAUX N.V., DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004008085

Country of ref document: DE

Representative=s name: VEREENIGDE OCTROOIBUREAUX V.O., DE

BERE Be: lapsed

Owner name: ANTISENSE PHARMA G.M.B.H.

Effective date: 20120831

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 369422

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120811

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20130430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130301

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004008085

Country of ref document: DE

Effective date: 20130301

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20131022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120812